Biocon - Global Healthcare Company
 
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > ABOUT US
  Overview
  Businesses
  Fact Sheet
  Mission
  People
  Quality
  History
  Awards
  Strategic Alliances
  
  Home
  
     
  Key Facts

General Information


Biocon Limited is a fully integrated biopharmaceutical company focused on biopharmaceuticals, custom research and clinical research.

Subsidiary Companies:

Syngene International Limited is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.

Clinigene International Limited is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors.

Biocon Biopharmaceuticals Private Limited (BBPL) is a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.

AxiCorp GmbH is a Friedrichsdorf (Germany) based pharmaceutical marketing company and is amongst the fastest growing in Europe. Biocon Limited acquired a majority stake in AxiCorp GmbH (70%) in February, 2008.

NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi. Incorporated in January 2008, NeoBiocon is a 50:50 joint venture with Dr. B.R.Shetty, Managing Director of NeoPharma, Abu Dhabi.

Intellectual Profile of 3600+ Personnel

Biocon, Syngene and Clinigene together employee approximately 3600 qualified personnel - from biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists to general administrators. 5% of our employees have PhD degrees, 41% have a master’s degree in science and the remaining are graduates with a bachelor's degree in science, commerce or arts. 15% of Biocon employees are women (across the group). The employee attrition last quarter was 7% and last year it was over 20%. The average age of the employees is 29 years.


Milestones

- Biocon is India's first biotechnology company, established
  in 1978

- Biocon is India's first biotechnology company to export
  microbial enzymes to USA and Europe

- Biocon is the first biotechnology company to receive ISO
  9001 certification in India

- Syngene, a Biocon subsidiary, is India's first custom
  research company in drug discovery

- Biocon is the first Indian company to be approved by
  US FDA for the manufacture of lovastatin, a
  cholesterol-lowering molecule

- Biocon's proprietary bioreactor, the PlaFractor™, receives a   US patent

- Biocon's subsidiary, Clinigene, has India's first CAP
  (College of American Pathologists) accredited clinical
  research laboratory, setting the benchmark for
  laboratories in India

- Biocon is awarded the Biotech Product and Process
  Development and Commercialisation Award, 2001 by
  the Department of Biotechnology, Ministry of Science
  and Technology, Government of India

- Syngene is awarded the Certificate of Excellence for
  Export Achievement by the Government of India, for
  two consecutive years 2002-2003

- Biocon is the first company, globally to manufacture
  human insulin, INSUGEN®, using a Pichia expression
  system, 2004

- Biocon launches BIOMAb EGFR™ India's first anti-cancer,   therapeutic Monoclonal Antibody-based drug for treating solid   tumors of epithelial origin, such as head & neck cancers, 2006

- Biocon divests its enzymes division to Novozymes, focuses   on biopharmaceuticals, 2007

- Syngene receives "BioServices Company of the Year",
  BioSpectrum Awards, 2007

- Biocon's BIOMAb EGFR™ wins "Product of the Year",
  BioSpectrum Awards, 2007

- Biocon acquires a 70% stake in German pharmaceutical   company, AxiCorp GmbH for a consideration of €30
  Million, 2008

- Biocon launches a Safety Device in the form of pre-filled   syringes for two of its life saving products, GCSF (granulocyte-  colony stimulating factor) and EPO (Erythropoietin) in   collaboration with Safety Syringes Inc. ERYPRO Safe™ and   NUFIL Safe™ are the first two drugs that will marketed using   this novel device with other injectable products to follow in the   future, 2008

- Biocon and Abraxis Bioscience launch ABRAXANE in India for   treatment of Breast Cancer, 2008

- Biocon is ranked among the top 20 global biotechnology   companies (Med Ad News), 2008

- Biocon is the 7th largest biotech employer in the world (Med   Ad News), 2008

- Biocon announced the results of an ascending dose study on   its oral insulin drug (IN-105) at the European Association for   the Study of Diabetes (EASD) meeting in Rome, 2008

- NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE   for the treatment of Breast Cancer, 2008

- Biocon's Syngene partners with Sapient Discovery to expand   integrated drug discovery offerings, 2009

- Biocon's Syngene and DuPont Crop Protection Forge Alliance   Partnership, 2009

- Bristol-Myers Squibb and Biocon's Syngene open new R&D   Facility at Biocon Park, 2009

- Biocon launches BASALOG - long lasting basal insulin for Type   1 & Type 2 Diabetics, 2009

- Biocon inks partnership with ISB to launch the Biocon Cell for   Innovation Management, 2009

- Biocon Announces Strategic Collaboration with Mylan to enter   the Global Generic Biologics Market, 2009


Products

Biopharmaceuticals

Active Pharmaceutical Ingredients (APIs)

- Anti-Diabetic Agents
- Anti-Inflammatory Agents
- Anti-Oxidants
- Cardiovascular Agents
- Anti-Obesity Agents
- Digestive-Aid Enzymes
- Anti-Hypertensive Agents
- Haemostatic Agents
- Hepatoprotective Agents
- Immunosuppressants
- Gastro-Intestinal Agents
- Nutraceuticals

Biologicals

- Insulin
- Streptokinase
- EPO
- GCSF
- Monoclonal Antibodies

Branded Formulations

Oncology

- BIOMAb EGFR®
- NUFIL safe (Pre-filled Syringe)
- NUFIL (Vials)
- Abraxane® for injectable suspension

Nephrology

- ERYPRO safe (Pre-filled Syringe)
- TACROGRAF
- RAPACAN
- CYCLOPHIL ME
- RENODAPT
- RENODAPT - S
- CeRACaL

Cardiology

- STATIX®
- STATIX®-F
- STATIX®-EZ
- BESTOR®
- TELMISAT
- TELMISAT-H
- ZARGO®
- ZARGO®-H
- ZIGPRIL®
- ACTIBLOK-IPR
- BRADIA
- CLASPRIN®
- THINRIN
- MYOKINASE
- CLOTIDE
- DYNALIX®

Diabetology

- INSUGEN®-R
- INSUGEN®-N
- INSUGEN®-30/70
- INSUGEN®-50/50
- BASALOG 3ml, 10 ml
- BLISTO 1, 2 & 4
- BLISTO-MF 1, 2 & 4
- METADOZE-IPR® 500 & 850
- PIODART®
- PIODART®-MF
- TriGPM
- ZUKER-MF
- GABIL
- GMAB Plus
- OLISAT

Dosage Forms

Biocon offers Indian pharmaceutical companies finished dosage formulations in the categories of cardiology, diabetology, nephrology, oncology and other specialised therapeutic segments. We provide formulations in the form of tablets, capsules, injections, liquid-orals and pellets.


Services

Licensing

Biocon collaboratively develops MAbs (Monoclonal Antibodies) and other novel drug delivery systems-based proteins either in-house or in partnership with other companies.

Contract Manufacturing

Biocon leverages its India cost base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele.

Research Services

Custom Research - Syngene

Chemistry
- Medicinal Chemistry
- Library Synthesis
- Process R&D
- Custom Manufacturing
- Analytical Services
- Polymer Chemistry

Biology
- Molecular Biology
- Protein Sciences
- Cell Lines Services
- Assay Services
- eADME/T&PK Studies
- Biologics
 
Clinical Research - Clinigene

- Clinical Operations
- Clinical Development
- Clinical Data Management and Biostatistics
- Regulatory Services
- Human Pharmacology unit
- Bioanalytical Research Laboratory
- Central Laboratory



Contact

Corporate Headquarters

20th KM Hosur Road
Electronics City
Bangalore 560 100
India
Phone: 91 80 2808 2808 / 91 80 4014 4014
Fax: 91 80 2852 3423
Email: contact.us@biocon.com

Overseas Representative Office

New Jersey
485 Route 1 South
Woodbridge Corporate Plaza
Building B Suite 305 lselin,
NJ 08830, USA
Phone: 732 636 2950
Fax: 732 636 2951
Email: abhijit.zutshi@biocon.com

London
Biocon Limited
50, Elm Quay Court
30, Nine Elms Lane
SW8 5DF, London
Phone: +44 2078199788
Fax: +44 2074502980
Mobile: +44 7515962466
Email: nehal.vora@biocon.com

Abu Dhabi
NeoBiocon
P.O. Box 72900
Abu Dhabi
United Arab Emirates
Phone: +971-2-550 1000
Fax: +971 -2- 550 1199
Mobile: +971 50 5826489
Email: sumit.bhanot@biocon.com

Human Resources

For careers at Biocon, please contact us at:
Phone: 91 80 2808 2808 / 91 80 4014 4014
Email: human.resources@biocon.com

Licensing/ Collaboration Opportunities

To submit licensing/collaboration opportunities
enquiries, please contact:
Mr. Sandeep Rao
General Manager - Business Development
Phone: 91 80 2808 2070
Email: sandeep.rao@biocon.com

Investor Relations

For investor related queries please contact:
Mr. Kiran Kumar
Company Secretary
Phone: 91 80 2808 2037
Email: investor.relations@biocon.com

Corporate Communications

For media related queries, please contact:
Ms. Paula Sengupta
Head - Corporate Communications
Phone: 91 80 2808 2808 / 91 80 4014 4014
Email: corporate.communications@biocon.com


Top

 
  Related links:
    Press Releases
    Discovery Pipeline
    Product Glossary
    Stock Info
 
Home  |  Contact Us  |  Site Map

BIOMAb e-CRF | INSUGEN® | Arogya Raksha Yojana | Biocon Foundation | ABLE | Karnataka Vision Group on Biotechnology | Karolinska Institute | Report Adverse Events/Side Effects and Products Complaints


 
  * Disclaimer | Authorised Users © 2008, Biocon. All Rights Reserved